Joyce Liu, MD, MPH
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
González-Martín A et al. Progression-free survival and safety at 3.5years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023;189:112908. Abstract
Hardesty MM et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166(2):219-29. Abstract
Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract
Paulet L et al. Cracking the homologous recombination deficiency code: How to identify responders to PARP inhibitors. Eur J Cancer 2022;166:87-99. Abstract
Ray-Coquard I et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92. Abstract
David M O’Malley, MD
Drew Y et al. Olaparib plus durvalumab, with or without bevacizumab, in platinum-sensitive relapse high-grade serous ovarian cancer: A phase II multi-cohort study (MEDIOLA). Clin Cancer Res 2024;30(1):50-62. Abstract
Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. ASCO 2023;Abstract LBA5506.
Herzog TJ et al. ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future Oncol 2023;19(23):1577-91. Abstract
Holloway R et al. Phase 3 study of efficacy & safety of OLVI-VEC and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (ONPRIMCE; GOG-3076). IGCS 2022;Abstract TPO26.
Winer I et al. Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: Recent data from ARTISTRY-1. SGO 2022;Abstract 077.
Kathleen N Moore, MD, MS
Marth C et al. Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial. ESGO 2023;Abstract 528.
Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. J Clin Oncol 2023;41(13):2436-45. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract
Moore KN et al. Mirvetuximab soravtansine in frα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;380(23):2162-74. Abstract
Mansoor Raza Mirza, MD
Matulonis U et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. SGO 2021;Abstract 11139.